UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G/A
(Amendment No. 4)
Under the Securities Exchange Act of 1934
Indevus Pharmaceuticals, Inc
Common Stock, no par value per share
(Title of Class of Securities)
454072109
CUSIP Number
December 31, 2003
(Date of Event which Requires Filing
of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
|_| Rule 13d-1(b)
|X| Rule 13d-1(c)
[ ] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
Continued on following pages
Page 1 of 5 Pages
SCHEDULE 13G
CUSIP No. 454072109 Page 2 of 5
--------------------------------------------------------------------------------
1 Names of Reporting Persons
I.R.S. Identification Nos. of above persons (entities only)
LINDSAY A. ROSENWALD, M.D.
--------------------------------------------------------------------------------
2 Check the Appropriate Box If a Member of a Group *
a. |_|
b. |X|
--------------------------------------------------------------------------------
3 SEC Use Only
--------------------------------------------------------------------------------
4 Citizenship or Place of Organization
UNITED STATES
--------------------------------------------------------------------------------
5 Sole Voting Power
Number of 3,078,463
Shares --------------------------------------------------------------
Beneficially 6 Shared Voting Power
Owned By 0
Each --------------------------------------------------------------
Reporting 7 Sole Dispositive Power
Person 3,078,463
With --------------------------------------------------------------
8 Shared Dispositive Power
0
--------------------------------------------------------------------------------
9 Aggregate Amount Beneficially Owned by Each Reporting Person
3,078,463
--------------------------------------------------------------------------------
10 Check Box If the Aggregate Amount in Row (9) Excludes Certain
Shares *
|_|
--------------------------------------------------------------------------------
11 Percent of Class Represented By Amount in Row (9)
6.47%
--------------------------------------------------------------------------------
12 Type of Reporting Person *
IN
--------------------------------------------------------------------------------
* see instructions before filling out
CUSIP No. 454072109 Page 3 of 5
Item 1(a) Name of Issuer:
Indevus Pharmaceuticals, Inc. (the "Issuer")
Item 1(b) Address of the Issuer's Principal Executive Offices:
99 Hayden Avenue
Lexington, MA 02421
(617) 861-8444
Item 2(a) Name of Person Filing:
This statement is filed on behalf of Lindsay A. Rosenwald, M.D. ("Dr. Rosenwald"
or the "Reporting Person").
Dr. Rosenwald is an investment banker, venture capitalist and fund manager.
Item 2(b) Address of Principal Business Office or, if None, Residence:
The address of the principal business office of Dr. Rosenwald is 787 Seventh
Avenue, 48th Floor, New York, New York, 10019.
Item 2(c) Citizenship:
Dr. Rosenwald is a citizens of the United States.
Item 2(d) Title of Class of Securities:
Common Stock (the "Shares").
Item 2(e) CUSIP Number:
454072109
Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or
(c), check whether the person filing is a:
This Item 3 is not applicable.
Item 4. Ownership:
Item 4(a) Amount Beneficially Owned:
The Reporting Person may be deemed the beneficial owner of the following
number of Shares:
Dr. Rosenwald may be deemed the beneficial owner of 3,078,463 Shares
as follows: (a) 2,147,481 Shares and options to purchase 302,501
Shares owned directly by Dr. Rosenwald and (b) 628,481 shares owned
by Rivki Rosenwald, Dr. Rosenwald's wife.
CUSIP No. 454072109 Page 4 of 5
Item 4(b) Percent of Class:
Please see Item 11 of each cover page.
Item 4(c) Number of shares as to which such person has:
(i) Sole power to vote or direct the vote: Please see Item 5 of each cover page
(ii) Shared power to vote or to direct the vote Please see Item 6 of each cover page
(iii) Sole power to dispose or to direct the disposition of Please see Item 7 of each cover page
(iv) Shared power to dispose or to direct the disposition of Please see Item 8 of each cover page
Item 5. Ownership of Five Percent or Less of a Class:
This Item 5 is not applicable.
Item 6. Ownership of More than Five Percent on Behalf of Another Person:
See Item 4(a)
Item 7. Identification and Classification of the Subsidiary Which Acquired the
Security Being Reported on by the Parent Holding Company:
This Item 7 is not applicable.
Item 8. Identification and Classification of Members of the Group:
This Item 8 is not applicable.
Item 9. Notice of Dissolution of Group:
This Item 9 is not applicable.
Item 10. Certification:
By signing below each of the Reporting Persons certifies that, to the best
of such person's knowledge and belief, the securities referred to above were not
acquired and are not held for the purpose of or with the effect of changing or
influencing the control of the Issuer of the securities and were not acquired
and are not held in connection with or as a participant in any transaction
having such purpose or effect.
Page 5 of 5
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, the
undersigned certifies that the information set forth in this statement is true,
complete and correct, as of this December 31, 2004.
LINDSAY A. ROSENWALD, M.D.
By /s/ Lindsay A. Rosenwald
--------------------------------------